A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
M-R-Vax Pharmacology, Pharmacokinetics, Studies, Metabolism - Measles and Rubella Virus Vaccine Live
M-R-Vax Pharmacology, Pharmacokinetics, Studies, Metabolism - Measles and Rubella Virus Vaccine Live
CLINICAL PHARMACOLOGY
Clinical studies of 237 double seronegative children, 10 months to 10 years
of age, demonstrated that M-R-VAX II is highly immunogenic and generally well
tolerated. In these studies, a single injection of the vaccine induced measles
hemagglutination-inhibition (HI) antibodies in 95 percent and rubella HI antibodies
in 99 percent of susceptible persons.
The RA 27/3 rubella strain in M-R-VAX II elicits higher immediate post-vaccination
HI, complement-fixing and neutralizing antibody levels than other strains of
rubella vaccine and has been shown to induce a broader profile of circulating
antibodies including anti-theta and anti-iota precipitating antibodies. The
RA 27/3 rubella strain immunologically simulates natural infection more closely
than other rubella vaccine viruses. The increased levels and broader profile
of antibodies produced by RA 27/3 strain rubella virus vaccine appear to correlate
with greater resistance to subclinical reinfection with the wild virus, and
provide greater confidence for lasting immunity.
Vaccine induced antibody levels following administration of M-R-VAX II have
been shown to persist up to 11 years without substantial decline. Continued
surveillance will be necessary to determine further duration of antibody persistence.
top
